210 related articles for article (PubMed ID: 36211409)
21. Elucidating the role of Pyroptosis in papillary thyroid cancer: prognostic, immunological, and therapeutic perspectives.
Li F; Du R; Kou J; Li J; Zhou L; Zhang D; Fu Y; Dionigi G; Bertoli S; Sun H; Liang N
Cancer Cell Int; 2024 Jan; 24(1):45. PubMed ID: 38287330
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
23. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
24. A Metabolic-associated Nomogram Predicts Recurrence Survival of Thyroid Cancer.
Xi ZH; Ma XX; Chen HY; Yu YH; Li L; Huang T
Curr Med Sci; 2021 Oct; 41(5):1004-1011. PubMed ID: 34510328
[TBL] [Abstract][Full Text] [Related]
25. TREM2 Is a Prognostic Biomarker and Correlated with an Immunosuppressive Microenvironment in Thyroid Cancer.
Wang J; Li Z
Dis Markers; 2022; 2022():1807386. PubMed ID: 36438899
[TBL] [Abstract][Full Text] [Related]
26. CXCL10 is a potential biomarker and associated with immune infiltration in human papillary thyroid cancer.
Qin XJ; Lin X; Xue G; Fan HL; Wang HY; Wu JF; Pei D
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33345267
[TBL] [Abstract][Full Text] [Related]
27. Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer.
Lin P; Guo YN; Shi L; Li XJ; Yang H; He Y; Li Q; Dang YW; Wei KL; Chen G
Aging (Albany NY); 2019 Jan; 11(2):480-500. PubMed ID: 30661062
[TBL] [Abstract][Full Text] [Related]
28. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
29. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
[TBL] [Abstract][Full Text] [Related]
30. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram.
Chen F; Li Z; Deng C; Yan H
J Cell Biochem; 2019 Dec; 120(12):19673-19683. PubMed ID: 31271223
[TBL] [Abstract][Full Text] [Related]
32. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract][Full Text] [Related]
33. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.
Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH
Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer.
Suh HY; Choi H; Paeng JC; Cheon GJ; Chung JK; Kang KW
BMC Cancer; 2019 Dec; 19(1):1260. PubMed ID: 31888560
[TBL] [Abstract][Full Text] [Related]
35. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
36. F12 as a reliable diagnostic and prognostic biomarker associated with immune infiltration in papillary thyroid cancer.
Luo JH; Zhang XX; Sun WH
Aging (Albany NY); 2022 Apr; 14(8):3687-3704. PubMed ID: 35483340
[TBL] [Abstract][Full Text] [Related]
37. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.
Zhang C; Bo C; Guo L; Yu P; Miao S; Gu X
World J Surg Oncol; 2019 Dec; 17(1):221. PubMed ID: 31842912
[TBL] [Abstract][Full Text] [Related]
38. A novel prognostic model for papillary thyroid cancer based on epithelial-mesenchymal transition-related genes.
Liu R; Cao Z; Pan M; Wu M; Li X; Yuan H; Liu Z
Cancer Med; 2022 Dec; 11(23):4703-4720. PubMed ID: 35608185
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma.
Gan X; Guo M; Chen Z; Li Y; Shen F; Feng J; Cai W; Xu B
J Endocrinol Invest; 2021 Oct; 44(10):2153-2163. PubMed ID: 33620716
[TBL] [Abstract][Full Text] [Related]
40. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
